Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SK-5307 single-dose Phase I study in healthy adult male subjects
jRCT2071220045Phase 1Completed
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of paltusotine (3 arms), sponsored by Sanwa Kagaku Kenkyusho Co., Ltd. Primary endpoints: Safety and tolerability of single-dose SK-5307 and Pharmacokinetics of SK-5307. Started Sep 2022; status: completed.
02
Drugs
paltusotine
Beyond the preview
Go deeper on jRCT2071220045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220045.